Phylogica, Genentech extend agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Phylogica Ltd. said Genentech has extended its exclusivity period for the research collaboration and license agreement to discover novel antibiotics utilizing Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.

A member of the Roche Group, Phylogica is a public Australian drug discovery company. Genentech is a member of the Roche Group.

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login